Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

12.99
-0.2500-1.89%
Post-market: 12.990.00000.00%19:30 EDT
Volume:1.16M
Turnover:15.05M
Market Cap:1.34B
PE:-9.61
High:13.18
Open:13.18
Low:12.67
Close:13.24
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:1.11
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.53
PE(LYR):-8.81

Loading ...

Oric Pharmaceuticals Inc: Proposed Deal For

THOMSON REUTERS
·
Jul 15

Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600

Reuters
·
Jul 09

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Oric Shareholders Approve Equity Plan, Governance Measures

TIPRANKS
·
Jun 23

Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan

Reuters
·
Jun 23

Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14

THOMSON REUTERS
·
Jun 12

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)

TIPRANKS
·
Jun 11

Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained

TIPRANKS
·
Jun 08

Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Jun 03

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Oric Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
May 06

ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts

TIPRANKS
·
May 05

Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
May 05

Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
May 05

Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo

TIPRANKS
·
May 05

Oric Pharmaceuticals price target lowered to $16 from $17 at Citi

TIPRANKS
·
May 05